Longevity & Anti-Aging
Extending healthy life: aging biology, cell therapies, regeneration
Overview
Understanding and intervening in the mechanisms of aging. Cell therapies, senescence, radical healthspan extension.
Impact: 20-40 more years of healthy life, healthcare costs -70%, massive human productivity
Involved actors
Roadmap
First senolytic drugs approved
UBX0101 or equivalent for osteoarthritis
Partial reprogramming trials Phase 2
Altos Labs human safety data
First combined therapy approvals
Senolytic + reprogramming combination regimen
Age-reversal 10+ years demonstrated
Comprehensive longevity stack efficacy
Projects
Active
Calico (Google) — Aging Research
Pipeline of 15+ programs targeting aging. Pharma collaborations, preclinical to clinical.
44% — 2026-2027
Altos Labs — Cellular Reprogramming
Partial reprogramming without dedifferentiation. Data: systemic rejuvenation in animal models.
52% — 2027-2028
Development
SENS Research Foundation — Regenerative Medicine
LIPL (Liver-In-A-Patch), partial reprogramming, senescent cell clearance.
38% — 2026-2027
Elevian — Systemic Rejuvenation (GDF11)
Phase II trial of GDF11 for Alzheimer's. Organ rejuvenation via systemic signaling.
42% — 2026-2027
Unity Biotechnology — Senolytic Drugs
Senolytic approach. Targeted clearance of senescent cells in age-related diseases.
35% — 2026